11 – 20 of 211
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Genetic insights into biological mechanisms governing human ovarian ageing
(
- Contribution to journal › Article
-
Mark
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
(
- Contribution to journal › Article
-
Mark
Genetic testing in women with early-onset breast cancer : a Traceback pilot study
(
- Contribution to journal › Article
-
Mark
Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
(
- Contribution to journal › Article
-
Mark
Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients
(
- Contribution to journal › Article
-
Mark
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
(
- Contribution to journal › Article
-
Mark
CYP3A7*1C allele : linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers
(
- Contribution to journal › Article
-
Mark
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
2021) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30(1). p.217-228(
- Contribution to journal › Article
-
Mark
Breast cancer risk factors and survival by tumor subtype : pooled analyses from the Breast Cancer Association Consortium
2021) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30(4). p.623-642(
- Contribution to journal › Article
-
Mark
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
(
- Contribution to journal › Article